Key result
Menopause status and age were strongly associated with higher levels of FASN tumor expression in early-stage breast cancer patients (P<0.005 and P=0.038, respectively).
Cohort (n=53)
FASN tumor expression is strongly associated with menopause status and age in early-stage breast cancer, suggesting it could be a potential therapeutic target in postmenopausal patients.
FASN-menopause association in early breast cancer should not change practice; hypothesis-generating for targeted therapy trials in postmenopausal patients.
OBJECTIVE: Overexpression of fatty acid synthase (FASN), the enzyme involved in the de novo synthesis of fatty acids, has been reported in several human carcinomas, including breast cancer, and has been related to poor prognosis. Our aim was to analyze the association of FASN tumor tissue expression with clinicopathological and anthropometrical features in early-stage breast cancer patients. METHODS: We prospectively studied 53 women with early-stage breast cancer who were treated with surgical operation and postoperative chemotherapy. RESULTS: Menopause status and age were strongly associated with higher levels of FASN tumor expression (P < 0.005 and P = 0.038, respectively). Body mass index and pathological stage were also related to FASN tumor expression. CONCLUSIONS: Our findings suggest that FASN could be a potential therapeutic target in postmenopausal breast cancer patients. However, further studies are needed.
No takes yet. Share an insight, caveat, or question.
Porta et al. (2013) conducted a cohort in Early-stage breast cancer (n=53). Menopause status and age was evaluated on FASN tumor tissue expression (p=<0.005). Menopause status and age were strongly associated with higher levels of FASN tumor expression in early-stage breast cancer patients (P<0.005 and P=0.038, respectively).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: